Baseline severity of depression predicts antidepressant drug response relative to escitalopram.

abstract：IMPORTANCE OF THE FIELD:Sorafenib is an oral receptor tyrosine kinase inhibitor that inhibits Raf serine/threonine kinases and receptor tyrosine kinases (vascular endothelial growth factor receptors 1, 2, 3 and platelet-derived growth factor-beta, Flt-3 and c-kit) that are implicated in tumorigenesis and tumor progress...

journal_title：Expert opinion on pharmacotherapy

authors： Iyer R,Fetterly G,Lugade A,Thanavala Y

更新日期：2010-08-01 00:00:00

abstract：INTRODUCTION:Hypertension is highly prevalent in patients with end-stage kidney disease on hemodialysis and is often not well controlled. Blood pressure (BP) levels before and after hemodialysis have a U-shaped relationship with cardiovascular and all-cause mortality. Although antihypertensive drugs are recommended for...

journal_title：Expert opinion on pharmacotherapy

authors： Maruyama T,Takashima H,Abe M

更新日期：2020-07-01 00:00:00

abstract：INTRODUCTION:The pharmacotherapeutic management of depression in patients with multiple sclerosis (MS) is a matter of debate that cannot be decided from the evidence available in the current literature. Therefore, its management essentially relies on the clinical experience of the prescribing clinician rather than on e...

journal_title：Expert opinion on pharmacotherapy

authors： Carta MG,Paribello P,Anastasia A,De Berardis D,Nardi AE,Fornaro M

更新日期：2018-10-01 00:00:00

abstract：:Initially it was considered that moxonidine, like clonidine, acted at central (2)-adrenoceptors to reduce blood pressure. With the characterisation of imidazoline binding sites distinct from (2)-adrenoceptors, the consensus became that moxonidine was acting predominantly at imidazoline I(1) receptors in the rostral ve...

journal_title：Expert opinion on pharmacotherapy

authors： Doggrell SA

更新日期：2001-02-01 00:00:00

abstract：:Memantine is the first and only medication that has been approved by European, US and Canadian regulatory agencies for the treatment of moderate-to-severe Alzheimer's disease (AD). It is an NMDA receptor antagonist that works to prevent excitotoxicity and cell death, which are mediated by the excessive influx of calci...

journal_title：Expert opinion on pharmacotherapy

authors： Cosman KM,Boyle LL,Porsteinsson AP

更新日期：2007-02-01 00:00:00

abstract：:Almotriptan is a serotonin (5-hydroxytryptamine, 5HT)(1B/1D)-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consi...

journal_title：Expert opinion on pharmacotherapy

authors： Dodick DW

更新日期：2003-07-01 00:00:00

abstract：INTRODUCTION:Immune-checkpoint inhibitor (ICPI) drugs, which include antibodies against CTLA-4, PD-1 and PD-L1, have been shown to induce durable complete responses in a proportion of patients with particular efficacy demonstrated in both the first line and refractory setting in advanced NSCLC and melanoma. However, th...

journal_title：Expert opinion on pharmacotherapy

authors： Flynn MJ,Larkin JMG

更新日期：2017-10-01 00:00:00

abstract：BACKGROUND:Fesoterodine is a newly approved drug for the treatment of overactive bladder syndrome. OBJECTIVE:The aim of this study was to review the preclinical and clinical data on fesoterodine. METHODS:The study involved a search of the Medline database and the proceedings volumes of urological congresses. RESULTS...

journal_title：Expert opinion on pharmacotherapy

authors： Michel MC

更新日期：2008-07-01 00:00:00

abstract：INTRODUCTION:Clostridium difficile infection (CDI) has become a significant healthcare-associated infection and is strongly associated with antibiotic use. Practice guidelines have recently been revised incorporating updated recommendations for diagnosis, treatment, and prevention. AREAS COVERED:This review discusses ...

journal_title：Expert opinion on pharmacotherapy

authors： Daniels LM,Kufel WD

更新日期：2018-11-01 00:00:00

abstract：INTRODUCTION:Chronic lymphocytic leukemia (CLL) often has an extended disease course. With a median age at diagnosis of 72 years, newer treatment options with less toxicity than standard nucleoside analogue-based regimens are needed. Historically, few therapy options are available once CLL has become refractory to nucl...

journal_title：Expert opinion on pharmacotherapy

authors： Chang JE,Kahl BS

更新日期：2012-07-01 00:00:00

abstract：:Overweight, obesity and the metabolic syndrome occur in genetically susceptible individuals with environmental influences, and may be further compounded by other disorders of metabolism or pharmacological therapy that increase insulin resistance or promotes weight gain. Treatment of the metabolic syndrome should focus...

journal_title：Expert opinion on pharmacotherapy

authors： Stone NJ,Schmeltz LR

更新日期：2007-09-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Diabetes mellitus is the most common endocrine disease in childhood. The global incidence of diabetes emphasizes the health, social and financial magnitude of this disease and the importance of optimizing disease management and prevention. AREAS COVERED IN THIS REVIEW:This article reviews the t...

journal_title：Expert opinion on pharmacotherapy

authors： Verrotti A,Chiuri RM,Blasetti A,Mohn A,Chiarelli F

更新日期：2010-10-01 00:00:00

abstract：INTRODUCTION:Tubulin inhibitors including taxanes and vinca alkaloids are important components of chemotherapy regimens used in advanced non-small cell lung cancer (NSCLC). Despite a treatment paradigm shift due to molecularly-targeted therapies and immunotherapy, a majority of patients will receive chemotherapy during...

journal_title：Expert opinion on pharmacotherapy

authors： Hardin C,Shum E,Singh AP,Perez-Soler R,Cheng H

更新日期：2017-05-01 00:00:00

abstract：INTRODUCTION:Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have become available for the treatment of this disease. Pemetrexed , a multi-target folate antagonist, has improved the survival of non-squamous...

journal_title：Expert opinion on pharmacotherapy

authors： Genova C,Rijavec E,Truini A,Coco S,Sini C,Barletta G,Dal Bello MG,Alama A,Savarino G,Pronzato P,Boccardo F,Grossi F

更新日期：2013-08-01 00:00:00

abstract：:Therapy of hepatitis C virus (HCV) infection may prevent progression to cirrhosis, hepatocellular carcinoma and end-stage liver disease. The cornerstone of treatment has long been standard IFN-alpha, the use of which was associated with a sustained biochemical and viral response in only a small proportion of patients....

journal_title：Expert opinion on pharmacotherapy

authors： Toniutto P,Fabris C,Pirisi M

更新日期：2006-10-01 00:00:00

abstract：:Genomic variations influencing response to pharmacotherapy of pain are under investigation. Candidate genes such as (opioid)-receptors, transporters and other molecules important for pharmacotherapy are discussed. Drug metabolising enzymes represent a further major target of ongoing research in order to identify assoc...

journal_title：Expert opinion on pharmacotherapy

authors： Stamer UM,Stüber F

更新日期：2007-10-01 00:00:00

abstract：:Introduction: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases and represents a leading cause of sudden cardiac death as well as a prevalent cause of heart failure and stroke. HCM is characterized by a very complex pathophysiology, consisting of heterogeneous clinical manifestations a...

journal_title：Expert opinion on pharmacotherapy

authors： Spoladore R,Fragasso G,Pannone L,Slavich M,Margonato A

更新日期：2020-02-01 00:00:00

abstract：INTRODUCTION:Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with a highly variable clinical course. Frontline treatments include cytotoxic chemotherapies, immunotherapies, and small molecule inhibitors. Clinical and molecular factors guide treatment initiation and selection. Over the last decade,...

journal_title：Expert opinion on pharmacotherapy

authors： Samples LS,Graf SA

更新日期：2018-10-01 00:00:00

abstract：:The Ras-Raf-MEK-ERK pathway is a ubiquitously expressed signalling module that regulates the proliferation, differentiation and survival of cells. This pathway features several oncogenes and is deregulated in approximately 30% of all human cancers. Thus, it has emerged as a prime target for antitumour therapy. Drugs t...

journal_title：Expert opinion on pharmacotherapy

authors： Kolch W

更新日期：2002-06-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Rhinosinusitis is a common illness that represents a substantial economic burden. The vast majority of cases resolve spontaneously but a small proportion develops a secondary bacterial infection. Accurate diagnosis of rhinosinusitis depends upon clinical assessment. Isolation of the causative ag...

journal_title：Expert opinion on pharmacotherapy

authors： Brook I

更新日期：2010-04-01 00:00:00

abstract：INTRODUCTION:Neratinib is an orally available, pan-HER inhibitor with clinical activity in patients with HER2-amplified and HER2-mutated breast cancer. Areas covered: A summary of publically available and relevant clinical data on neratinib. Expert opinion: Neratinib (N) is clearly distinct from lapatinib (L), a differ...

journal_title：Expert opinion on pharmacotherapy

authors： Prové A,Dirix L

更新日期：2016-11-01 00:00:00

abstract：INTRODUCTION:Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepi...

journal_title：Expert opinion on pharmacotherapy

authors： Striano P,Belcastro V

更新日期：2013-07-01 00:00:00

abstract：:Staphylococcus aureus is a bacterial pathogen responsible for a variety of serious infections and is a frequent cause of nosocomial disease. During the last 60 years, S. aureus has developed increasing in vitro resistance to virtually all antimicrobials. In contrast, vancomycin has maintained a high degree of activity...

journal_title：Expert opinion on pharmacotherapy

authors： Pope SD,Roecker AM

更新日期：2007-06-01 00:00:00

abstract：INTRODUCTION:Glaucoma is the second leading cause of blindness globally, representing a significant public health concern. More than 60 million people are affected by glaucoma worldwide; as this population ages, the number is expected to increase. Glaucoma is a collection of heterogeneous diseases sharing common clinic...

journal_title：Expert opinion on pharmacotherapy

authors： Konstas AG,Quaranta L,Realini T

更新日期：2012-04-01 00:00:00

abstract：PURPOSE:To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). METHODS:Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pr...

journal_title：Expert opinion on pharmacotherapy

authors： Rossi GC,Pasinetti GM,Sandolo F,Bordin M,Bianchi PE

更新日期：2011-11-01 00:00:00

abstract：:Thirty to forty percent of patients with idiopathic membranous nephropathy have persistent heavy proteinuria and may progress to end-stage kidney disease in 5 - 15 years. The ideal treatment for these patients is a matter of debate. Several nonspecific immunosuppressive regimens have been suggested with the aim of red...

journal_title：Expert opinion on pharmacotherapy

authors： Ruggenenti P,Cravedi P,Remuzzi G

更新日期：2007-12-01 00:00:00

abstract：:At least two factors relating to pain management using oral analgesics suggest that combination strategies merit consideration: many pains arise from more than one physiological cause and current analgesics have adverse effect profiles that might be reduced by combination with another agent in smaller doses or with le...

journal_title：Expert opinion on pharmacotherapy

authors： Raffa RB,Clark-Vetri R,Tallarida RJ,Wertheimer AI

更新日期：2003-10-01 00:00:00

abstract：INTRODUCTION:Epilepsy is a serious and common chronic neurological disease with an urgent need for novel treatment options, because 30% of all epilepsy patients do not respond to currently available drugs. Retigabine/Ezogabine (RTG) is a third-generation antiepileptic drug (AED) with a novel mechanism of action. It enh...

journal_title：Expert opinion on pharmacotherapy

authors： Orhan G,Wuttke TV,Nies AT,Schwab M,Lerche H

更新日期：2012-08-01 00:00:00

abstract：:Ankylosing spondylitis (AS) is a frequent disease leading to functional impairment and socioeconomic burden. Anti-TNF-alpha therapy has brought new perspectives in this condition. Two agents are currently used in the treatment of AS and spondyloarthropathies - infliximab (a chimeric monoclonal antibody) and etanercept...

journal_title：Expert opinion on pharmacotherapy

authors： Wendling D,Toussirot E

更新日期：2004-07-01 00:00:00

abstract：:Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial ...

journal_title：Expert opinion on pharmacotherapy

authors： Piérard GE,Arrese JE,Piérard-Franchimont C

更新日期：2000-01-01 00:00:00